Asia Pacific Asthma Drugs Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication (Quick Relief Medications and Long-Term Control Medications), Route of Administration (Inhaled, Prefilled Syringe/Vials, and Others), and Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies)

No. of Pages: 153    |    Report Code: BMIRE00025216    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Asthma Drugs Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific Asthma Drugs Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Asia Pacific Asthma Drugs Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 The Rising Prevalence of Asthma Leads to an Increase in Demand for Asthma Drugs, Favors the Market Growth
5.2 Market Opportunities
  • 5.2.1 Commercialization of Biologics Creates Significant Opportunities in the Market
5.3 Future Trends
  • 5.3.1 Research Activities and Product Innovations
5.4 Impact of Drivers and Restraints

6. Asia Pacific Asthma Drugs Market Regional Analysis

6.1 Asia Pacific Asthma Drugs Market Overview
6.2 Asia Pacific Asthma Drugs Market Revenue 2019-2028 (US$ Million)
6.3 Asia Pacific Asthma Drugs Market Forecast Analysis

7. Asia Pacific Asthma Drugs Market Analysis – by Medication

7.1 Quick Relief Medications
  • 7.1.1 Overview
  • 7.1.2 Quick Relief Medications: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Long-Term Control Medications
  • 7.2.1 Overview
  • 7.2.2 Long-Term Control Medications: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Asthma Drugs Market Analysis – by Route of Administration

8.1 Inhaled
  • 8.1.1 Overview
  • 8.1.2 Inhaled: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Prefilled Syringe/Vials
  • 8.2.1 Overview
  • 8.2.2 Prefilled Syringe/Vials: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Asthma Drugs Market Analysis – by Distribution Channel

9.1 Online Pharmacies
  • 9.1.1 Overview
  • 9.1.2 Prefilled Syringe/Vials: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Hospital Pharmacies
  • 9.2.1 Overview
  • 9.2.2 Prefilled Syringe/Vials: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
9.3 Retail Pharmacies
  • 9.3.1 Overview
  • 9.3.2 Prefilled Syringe/Vials: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Asthma Drugs Market – Asia-Pacific Analysis

10.1 Asia-Pacific
  • 10.1.1 Asia Pacific Asthma Drugs Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 Asia Pacific Asthma Drugs Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 China: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 China: Asia Pacific Asthma Drugs Market Breakdown, by Medication
    • 10.1.1.1.2 China: Asia Pacific Asthma Drugs Market Breakdown, by Route of Administration
    • 10.1.1.1.3 China: Asia Pacific Asthma Drugs Market Breakdown, by Distribution Channel
  • 10.1.1.2 India: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 India: Asia Pacific Asthma Drugs Market Breakdown, by Medication
    • 10.1.1.2.2 India: Asia Pacific Asthma Drugs Market Breakdown, by Route of Administration
    • 10.1.1.2.3 India: Asia Pacific Asthma Drugs Market Breakdown, by Distribution Channel
  • 10.1.1.3 Japan: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Japan: Asia Pacific Asthma Drugs Market Breakdown, by Medication
    • 10.1.1.3.2 Japan: Asia Pacific Asthma Drugs Market Breakdown, by Route of Administration
    • 10.1.1.3.3 Japan: Asia Pacific Asthma Drugs Market Breakdown, by Distribution Channel
  • 10.1.1.4 Australia: Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Australia: Asia Pacific Asthma Drugs Market Breakdown, by Medication
    • 10.1.1.4.2 Australia: Asia Pacific Asthma Drugs Market Breakdown, by Route of Administration
    • 10.1.1.4.3 Australia: Asia Pacific Asthma Drugs Market Breakdown, by Distribution Channel
  • 10.1.1.5 Rest of Asia-Pacific : Asia Pacific Asthma Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Asthma Drugs Market Breakdown, by Medication
    • 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Asthma Drugs Market Breakdown, by Route of Administration
    • 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Asthma Drugs Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Asia Pacific Asthma Drugs Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AstraZeneca
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Boehringer Ingelheim International GmbH
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 GlaxoSmithKline plc.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Merck & Co., Inc.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Koninklijke Philips N.V.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Sanofi
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Novartis AG
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments
13.11 Abbott
  • 13.11.1 Key Facts
  • 13.11.2 Business Description
  • 13.11.3 Products and Services
  • 13.11.4 Financial Overview
  • 13.11.5 SWOT Analysis
  • 13.11.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - Asia Pacific Asthma Drugs Market

  1. AstraZeneca
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD
  3. GlaxoSmithKline plc.
  4. Boehringer Ingelheim International GmbH
  5. GlaxoSmithKline plc.
  6. Merck & Co., Inc.
  7. Koninklijke Philips N.V.
  8. Sanofi
  9. Pfizer Inc. (Arena Pharmaceutical GmbH)
  10. Novartis AG
  11. Abbott